ReillyGD, SpencerRC. Pseudomonic acid-a new antibiotic for skin infections.J Antimicrob Chemother1984; 13: 295–8.
2.
WardA, Campoli-RichardsDM. Mupirocin: a review of its anti-bacterial activity, pharmacokinetic properties and therapeutic use.Drugs1986; 32: 425–44.
3.
BlumerJL, LemonE, O'HOROJ, SnodgrassDJ. Changing therapy for skin and soft tissue infections in children: have we come full circle?Pediatr Infect Dis1987; 6: 117–22.
4.
EellsLD, MertzPM, PiovanettiY. Topical antibiotic treatment of impetigo with mupirocin.Arch Dermatol1986; 122: 1273–6.
5.
OrecchioRM, MischlerTW. A double-blind multiclinic comparative trial of mupirocin topical and its vehicle in the treatment of bacterial skin infections.Curr Ther Res Clin Exp1986; 39: 82–6.
6.
DuxPH, FieldsL, PollockD. 2% topical mupirocin versus systemic erythromycin and cloxacillin in primary and secondary skin infections.Curr Ther Res1986; 40: 933–40.
7.
Guertin-LarochelleS. Efficacy and tolerance of topical Bactroban (2% mupirocin) vs. systemic cloxacillin in the treatment of primary and secondary skin infections.Today's Ther Trends1986; 4: 1–14.
8.
ArredondoJL. Efficacy and tolerance of topical mupirocin compared with oral dicloxacillin in the treatment of primary skin infections.Curr Ther Res1987; 41: 121–7.
9.
WelshO, SaenzC. Topical mupirocin compared with oral ampicillin in the treatment of primary and secondary skin infections.Curr Ther Res1987; 41: 114–20.
